PRAETORIAN试验:皮下与经静脉ICD适当电击及抗心动过速起搏的疗效与安全性
PRAETORIAN试验预设二次分析比较皮下ICD(S-ICD)与经静脉ICD(TV-ICD)的适当治疗,849例患者随机分组随访中位49.1个月。S-ICD组更多患者接受至少一次电击(48个月19.2% vs 11.5%,P=0.02),但两组总适当电击数无差异,首次电击 efficacy 相似。抗心动过速起搏首次终止46%单形性室速但9.4%加速心律失常。
要点
- S-ICD组接受至少一次适当电击的患者比例高于TV-ICD组(19.2% vs 11.5%,P=0.02)。
- 两组适当治疗患者比例、总适当电击数及首次电击 efficacy 均无显著差异。
- 抗心动过速起搏首次终止46%单形性室速,但9.4%出现心律失常加速。
核心结论
- S-ICD与TV-ICD在适当电击疗效上无差异,但S-ICD组更多患者接受至少一次电击,总适当电击数无差异。
研究设计与样本
- 国际研究者发起的随机试验,39个中心纳入849例有ICD适应症患者,随机分配至S-ICD组(n=426)或TV-ICD组(n=423),中位随访49.1个月,按方案设定ICD编程。
主要发现
- S-ICD组86/426例接受适当治疗,TV-ICD组78/423例,48个月Kaplan-Meier估计19.4% vs 17.5%(P=0.45)。
- S-ICD组83例接受至少1次电击,TV-ICD组57例,48个月估计19.2% vs 11.5%(P=0.02)。
- S-ICD组总电击254次,TV-ICD组228次(P=0.68);首次电击 efficacy 93.8% vs 91.6%(P=0.40)。
- 首次抗心动过速起搏成功终止46%单形性室速,9.4%出现心律失常加速。
关键数值与推荐
- 适当ICD治疗定义为针对室性心律失常的治疗;心律失常分为独立发作和电风暴(24小时内≥3次发作)。
临床怎么用
- S-ICD不能提供抗心动过速起搏,临床选择需权衡电击负担与抗心动过速起搏获益。
- 对于单形性室速,抗心动过速起搏首次终止率46%但9.4%加速,需警惕其风险。
局限性
- 原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) showed noninferiority of subcutaneous implantable cardioverter defibrillator (S-ICD) compared with transvenous implantable cardioverter defibrillator (TV-ICD) with regard to inappropriate shocks and complications. In contrast to TV-ICD, S-ICD cannot provide antitachycardia pacing for monomorphic ventricular tachycardia. This prespecified secondary analysis evaluates appropriate therapy and whether antitachycardia pacing reduces the number of appropriate shocks. METHODS: The PRAETORIAN trial was an international, investigator-initiated randomized trial that included patients with an indication for implantable cardioverter defibrillator (ICD) therapy. Patients with previous ventricular tachycardia <170 bpm or refractory recurrent monomorphic ventricular tachycardia were excluded. In 39 centers, 849 patients were randomized to receive an S-ICD (n=426) or TV-ICD (n=423) and were followed for a median of 49.1 months. ICD programming was mandated by protocol. Appropriate ICD therapy was defined as therapy for ventricular arrhythmias. Arrhythmias were classified as discrete episodes and storm episodes (≥3 episodes within 24 hours). Analyses were performed in the modified intention-to-treat population. RESULTS: In the S-ICD group, 86 of 426 patients received appropriate therapy, versus 78 of 423 patients in the TV-ICD group, during a median follow-up of 52 months (48-month Kaplan-Meier estimates 19.4% and 17.5%; P=0.45). In the S-ICD group, 83 patients received at least 1 shock, versus 57 patients in the TV-ICD group (48-month Kaplan-Meier estimates 19.2% and 11.5%; P=0.02). Patients in the S-ICD group had a total of 254 shocks, compared with 228 shocks in the TV-ICD group (P=0.68). First shock efficacy was 93.8% in the S-ICD group and 91.6% in the TV-ICD group (P=0.40). The first antitachycardia pacing attempt successfully terminated 46% of all monomorphic ventricular tachycardias, but accelerated the arrhythmia in 9.4%. Ten patients with S-ICD experienced 13 electrical storms, versus 18 patients with TV-ICD with 19 electrical storms. Patients with appropriate therapy had an almost 2-fold increased relative risk of electrical storms in the TV-ICD group compared with the S-ICD group (P=0.05). CONCLUSIONS: In this trial, no difference was observed in shock efficacy of S-ICD compared with TV-ICD. Although patients in the S-ICD group were more likely to receive an ICD shock, the total number of appropriate shocks was not different between the 2 groups. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01296022.
引用
- Knops RE, van der Stuijt W, Delnoy PPHM, et al. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. Circulation. 2021. PMID: 34779221. doi:10.1161/CIRCULATIONAHA.121.057816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。